ArticleInternational journal of experimental pathology1990
Effect of tumour promoters on poly ADP-ribosylation in human epidermoid carcinoma HeP2 cells.
Article in International journal of experimental pathology, 1990. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 8 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The present work was undertaken with the basic objective to compare the effect of related tumour promoters phorbol-12-myristate-13-acetate (PMA), benzoyl peroxide (BP) and mezerein (M) on poly ADP-ribosylation in HeP2 cells. PMA, BP and mezerein showed an increase in the enzyme activity to the extent of 66, 89 and 35% respectively. This was accompanied by a drop in NAD levels of 22% with PMA, 24% with BP and 49% with mezerein, PMA-treated cells showed a decrease in the enzyme activity of 42% with superoxide dismutase (SOD) and catalase (CAT), 18% with butylated hydroxy toluene (BHT), 52% with indomethacin and 32% with 3-aminobenzamine (3AB). However, for BP the inhibition was 16% with CAT, 41% with SOD, 18% with BHT, 34% with 3AB and there was no inhibition with indomethacin. The involvement of active oxygen species was supported by a 2.5-fold increase in superoxide anion levels with PMA and BP and no change with mezerein. There was a twofold and a 2.5-fold increase in Ca2+ influx after PMA and BP treatment respectively. It is concluded that PMA and BP mediate their effect on poly ADP-ribosylation through active oxygen species which in turn stimulates the influx of Ca2+ into cells and this may play an important role in signal transduction.
Indexed as
Identifiers
2126186PMC2002381W2254193828What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.